Article info
PDFClinical and epidemiological research
Extended report
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
- Correspondence to Dr Pierre Quartier, Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Hopital Necker-Enfants Malades, 149 rue de Sevres 75 015 Paris, France; pierre.quartier{at}nck.aphp.fr
Citation
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
Publication history
- Accepted November 11, 2010
- First published December 20, 2010.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Web Only Data
Files in this Data Supplement:
Web Only Data
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl